FDA Grants Priority Review for Dupixent® (dupilumab) as Potential Treatment for Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis
Go back to FDA Grants Priority Review for Dupixent® (dupilumab) as Potential Treatment for Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis| Regeneron (NASDAQ: REGN) | Delayed: 784.85 -4.6 (0.58%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $789.45 | 52 Week High | $592.36 | |||
| Open | $787.34 | 52 Week Low | $325.35 | |||
| Day High | $794.73 | P/E | 206.00 | |||
| Day Low | $779.65 | EPS | $3.81 | |||
| Volume | 2,473,425 | |||||
